The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing

Annual Review of Pharmacology and Toxicology

Volumn 42, Issue , 2002, Pages 553-583

  Svensson, Camilla I ^a   Yaksh, Tony L ^a  

^a University of California   (United States)

Author keywords

COX; Hyperalgesia; Intrathecal; Isozymes; Pain; PLA2

Indexed keywords

PHOSPHOLIPASE; PROSTAGLANDIN SYNTHASE; PROSTANOID;

ANIMAL TISSUE; ENZYME LOCALIZATION; GENE EXPRESSION REGULATION; HYPERALGESIA; NERVE EXCITABILITY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RECEPTOR UPREGULATION; RELIABILITY; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD; TISSUE INJURY; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; HYPERALGESIA; PAIN; PHOSPHOLIPASES A; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SIGNAL TRANSDUCTION; SPINAL CORD; TRANS-ACTIVATION (GENETICS);

ANIMALIA;

EID: 0036172409     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.42.092401.143905     Document Type: Review

References (227)

1. Certain aspects of the pharmacology of the salicylates
2. The morphine sparing effect of ketorolac tromethamine. A study of a new, parenteral non-steroidal anti-inflammatory agent after abdominal surgery
3. Double-blind controlled trial of indomethacin as an adjunct to narcotic analgesia after major abdominal surgery
4. Analgesic drug therapy in cancer pain: Principles and practice
5. Changing attitudes towards narcotic use in cancer pain management in Japan
6. Paracetamol with and without codeine in acute pain: A quantitative systematic review
7. Role of spinal cyclo-oxygenases in nociceptive processing
8. Analgesies and antipyretics
9. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
10. Aspirin selectively inhibits prostaglandin production in human platelets
11. Pain
12. Prostaglandins, aspirin-like drugs and analgesia
13. Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of aspirin-like drugs in the dog knee joint
14. Dissociation between the antinociceptive and antiinflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy
15. The spinal biology in humans and animals of pain states generated by persistent small afferent input
16. Regulation of ligandgated ion channels by protein phosphorylation
17. The growing phospholipase A2 superfamily of signal transduction enzymes
18. A reassessment of the low molecular weight phospholipase A2 gene family in mammals
19. Prostacyclin enhances the evoked-release of substance P and calcitonin gene-related peptide from rat sensory neurons
20. Prostaglandin E2 enhances bradykinin-stimulated release of neuropeptides from rat sensory neurons in culture
21. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat
22. Spinal neurokinin NK1 receptor down-regulation and antinociception: Effects of spinal NK1 receptor antisense oligonucleotides and NK1 receptor occupancy
23. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model
24. Immune activation: The role of proinflammatory cytokines in inflammation, illness responses and pathological pain states
25. Dynamic regulation of proinflammatory cytokines
26. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat
27. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat
28. Cytokines regulate expression of the type 1 interleukin-1 receptor in rat hippocampal neurons and glia
29. Expression and regulation of cyclooxygenase-2 in rat microglia
30. Diversity of group types, regulation, and function of phospholipase A2
31. cPLA2 is phosphorylated and activated by MAP kinase
32. Cytosolic phospholipase A2
33. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid
34. Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages
35. Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages
36. Mobilization of different arachidonate pools and their roles in the generation of leukotrienes and free arachidonic acid during immunologic activation of mast cells
37. Immunocytochemical localization of cPLA2 in rat and monkey spinal cord
38. Distribution of cytoplasmic phospholipase A2 in the normal rat brain
39. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity
40. The human calcium-independent phospholipase A2 gene multiple enzymes with distinct properties from a single gene
41. Effect of spinal administration of phospholipase A2 inhibitors on carrageenan and formalin induced inflammatory hyperalgesia
42. Interleukin-1 beta induces cytosolic phospholipase A2 gene in rats C6 glioma cell line
43. Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes
44. Selective inhibition of cytosolic phospholipase A2 in activated human monocytes. Regulation of superoxide anion production and low density lipoprotein oxidation
45. Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression
46. Cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC): Response to genistein and pyrrolidine dithiocarbamate
47. Signal transduction pathways involved in the synergistic stimulation of prostaglandin production by interleukin1beta and tumor necrosis factor alpha in human gingival fibroblasts
48. Regulation and inhibition of phospholipase A2
49. Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells
50. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets
51. Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist
52. Methyl arachidonyl fluorophosphonate: A potent irreversible inhibitor of anandamide amidase
53. Interfacial activation, lysophospholipase and transacylase activity of group VI Ca2+independent phospholipase A2
54. Prostaglandin endoperoxide synthases-1 and -2
55. Arachidonic acid oxygenation by COX1 and COX-2. Mechanisms of catalysis and inhibition
56. Cyclooxygenases 1 and 2
57. Prostaglandin synthase 2
58. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
59. Constitutive expression of cyclooxygenase-2 in rat vas deferens
60. Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics
61. Cyclooxygenase-1 is a marker for a subpopulation of putative nociceptive neurons in rat dorsal root ganglia
62. Increased levels of cyclooxygenase-2 mRNA in the rat spinal cord after peripheral inflammation: An in situ hybridization study
63. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvantinduced arthritis
64. Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord
65. Upregulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
66. Dexamethasone prevents the induction of COX-2 mRNA and prostaglandins in the lumbar spinal cord following intraplantar FCA in parallel with inhibition of oedema
67. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability
68. The intraspinal release of prostaglandin E2 in a model of acute arthritis is accompanied by an up-regulation of cyclo-oxygenase-2 in the spinal cord
69. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis
70. Cellular localization and distribution of COX-2 in rat spinal cord
71. Localization and regulation of cyclo-oxygenase1 and -2 and neuronal nitric oxide synthase in mouse spinal cord
72. Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord
73. Role of cyclooxygenase 2 in acute spinal cord injury
74. Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord
75. 2 is mediated by the inhibition of constitutive spinal COX2 but not COX-1
76. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex
77. Time dependent upregulation of spinal COX-2 after peripheral injection of carrageenan
78. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen
79. Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system
80. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2
81. Brain endothelial cells express cyclooxygenase-2 during lipopolysaccharide-induced fever: Light and electron microscopic immunocyto chemical studies
82. Functional characterization of substance P receptors on cultured human spinal cord astrocytes: Synergism of substance P with cytokines in inducing interleukin6 and prostaglandin E2 production
83. In vitro prostanoid release from spinal cord following peripheral inflammation: Effects of substance P, NMDA and capsaicin
84. Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats
85. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats
86. Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future
87. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat
88. Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction
89. Role of spinal cyclooxygenase (COX)2 on thermal hyperalgesia evoked by carageenan injection in the rat
90. COX-2 inhibitor prevents the development of hyperalgesia induced by intrathecal NMDA or AMPA
91. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition
92. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor
93. Nonsteroidal antiinfiammatory drug modulation of behavioral responses to intrathecal N-methyl-D-aspartate, but not to substance P and amino-methyl-isoxazolepropionic acid in the rat
94. Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses
95. Comparative effects of cyclo-oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance
96. Effect of spinal cyclooxygenase inhibitors in rat using the formalin test and in vitro prostaglandin E2 release
97. Spinal actions of cyclooxygenase isozyme inhibitors
98. Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: A microdialysis study in unanesthetized rats
99. Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS deficient mice
100. Intrathecal ketorolac tromethamine produces analgesia after chronic constriction injury of sciatic nerve in rat
101. Spinal cyclooxygenase-2 is involved in development of allodynia after nerve injury in rats
102. Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerveinjured rats
103. Diclofenac evaluated in a human experimental model of central pain
104. N-methyl D-aspartate induced mechanical allodynia is blocked by nitric oxide synthase and cyclooxygenase-2 inhibitors
105. Capsaicin-evoked prostaglandin E2 release in spinal cord slices: Relative effect of cyclooxygenase inhibitors
106. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways
107. Eicosanoids in the central nervous system
108. Nociception in cyclooxygenase isozyme-deficient mice
109. The eicosanoids and their biochemical mechanisms of action
110. Eicosanoids in synaptic transmission
111. pH-metric log P. 6. Effects of sodium, potassium, and N-CH3-D glucamine on the octanol-water partitioning of prostaglandins E1 and E2
112. Apical-basolateral membrane asymmetry in canine cortical collecting tubule cells. Bradykinin, arginine vasopressin, prostaglandin E2 interrelationships
113. Impermeability of rabbit erythrocytes to prostaglandins
114. Molecular mechanisms of prostaglandin transport
115. Cyclooxygenase-dependent signalling: Molecular events and consequences
116. Aspects of the thromboxane receptor system
117. Molecular mechanisms of diverse actions of prostanoid receptors
118. Prostanoid receptors: Structures, properties, and functions
119. Receptor-effector coupling by G proteins
120. Species differences in the effects of prostaglandins on inositol trisphosphate accumulation, phosphatidic acid formation, myosin light chain phosphorylation and contraction in iris sphincter of the mammalian eye: Interaction with the cyclic AMP system
121. Pertussis toxin abolishes the inhibitory effects of prostaglandins E1, E2, I2 and F2 alpha on hormone-induced cAMP accumulation in cultured hepatocytes
122. Prostaglandin E receptors in bovine adrenal medulla are coupled to adenylate cyclase via Gi and to phosphoinositide metabolism in a pertussis toxin-insensitive manner
123. Expression of prostaglandin EP2 receptor mRNA in the rat spinal cord
124. Expression and regulation of prostaglandin E receptor subtype mRNAs in rat sensory ganglia and spinal cord in response to peripheral inflammation
125. Prostacyclin receptor in the brain and central terminals of the primary sensory neurons: An autoradiographic study using a stable prostacyclin analogue [3H]iloprost
126. A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor
127. In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs
128. The effect of morphine on formalin-evoked behaviour and spinal release of excitatory amino acids and prostaglandin E2 using microdialysis in conscious rats
129. Noxious stimulus-induced increase in spinal prostaglandin E2 is noradrenergic terminaldependent
130. Neonatal capsaicin treatment abolishes formalin-induced spinal PGE2 release
131. Characterization of time course of spinal amino acids, citrulline and PGE2 release after carrageenan/kaolin-induced knee joint inflammation: A chronic microdialysis study
132. Inhibition of spinal protein kinase C reduces nerve injury-induced tactile allodynia in neuropathic rats
133. Effect of spinal kainic acid receptor activation on spinal amino acid and prostaglandin E2 release in rat
134. The role of IP prostanoid receptors in inflammatory pain
135. Prostaglandin E2 increases calcium conductance and stimulates release of substance P in avian sensory neurons
136. Prostaglandins suppress an outward potassium current in embryonic rat sensory neurons
137. Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors
138. Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A
139. Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system
140. Release of amino acids and PGE2 into the spinal cord of lightly anesthetized rats during devvelopment of an experimental arthritis: Enhancement of C-fiber evoked release
141. Direct activation of rat spinal dorsal horn neurons by prostaglandin E2
142. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
143. Allodynia ev.oked by intrathecal administration of prostaglandin F2 alpha to conscious mice
144. Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice
145. Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice
146. Intrathecal prostaglandin E1 produces a long-lasting allodynic state
147. The enhancement of formalin induced agitation behavior by intrathecal administration of prostaglandin E1
148. Intrathecal administration of prostaglandin E2 causes sensitization of the primary afferent neuron via the spinal release of glutamate
149. L-NAME, an inhibitor of nitric oxide synthase, blocks the established allodynia induced by intrathecal administration of prostaglandin E2
150. The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia
151. Nociceptive action of excitatory amino acids in the mouse: Effects of spinally administered opioids, phencyclidine and sigma agonists
152. Arachidonic acid as a messenger for the expression of longterm potentiation
153. Contribution of endogenously formed arachidonic acid in the presynaptic facilitatory effects of NMDA and carbachol on dopamine release in the mouse striatum
154. Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons
155. Pre- versus postformalin effects of ketamine or large-dose alfentanil in the rat: Discordance between pain behavior and spinal Fos-like immunoreactivity
156. Pre- versus postinjury effects of intravenous GABAergic anesthetics on formalin-induced Fos immunoreactivity in the rat spinal cord
157. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord
158. Comparison of the effects of treatment with intrathecal lidocaine given before and after formalin on both nociception and Fos expression in the spinal cord dorsal horn
159. Intrathecally administered c-fos antisense oligodeoxynucleotide decreases formalin-induced nociceptive behavior in adult rats
160. Formalin-evoked activity in identified primary afferent fibers: Systemic lidocaine suppresses phase-2 activity
161. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2
162. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
163. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain
164. Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide
165. 5′-Flanking region surrounding a human cytosolic phospholipase A2 gene
166. Aspirin inhibits expression of the interleukin-1 beta-inducible group II phospholipase A2
167. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta
168. Transcriptional roles of nuclear factor kappaB and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells
169. Transcriptional role of the nuclear factor kappaB site in the induction by lipopolysaccharide and suppression by dexamethasone of cyclooxygenase-2 in U937 cells
170. Superinduction of COX-2 mRNA by cycloheximide and interleukin-1 beta involves increased transcription and correlates with increased NF-kappaB and JNK activation
171. Ca2+-mediated activation of c-Jun N-terminal kinase and nuclear factor kappaB by NMDA in cortical cell cultures
172. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum
173. NF-kappaB induction during in vivo hypoxia in dorsocaudal brain stem of rat: Effect of MK-801 and L-NAME
174. Synaptic activation of NF-kappaB by glutamate in cerebellar granule neurons in vitro
175. Induction of cyclooxygenase-2 expression in human myometrial smooth muscle cells by interleukin-1 beta: Involvement of p38 mitogen-activated protein kinase
176. Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway
177. Interleukin-1 beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes
178. Role of ERK MAP kinases in responses of cultured human airway smooth muscle cells to IL-1 beta
179. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes
180. 2 biosynthesis by IL-1β is mediated by PKC and mitogen-activated protein kinases in murine astrocytes
181. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA
182. Tumor necrosis factor-alpha-induced cyclooxygenase-2-expression via sequential activation of ceramide dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells
183. p38 mitogen-activated protein kinase regulates cyclooxygenase2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes
184. Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages
185. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages
186. Regulation of nitric oxide and prostaglandin E2 production by CSAIDS (SB203580) in murine macrophages and bovine chondrocytes stimulated with LPS
187. Involvement of mitogen-activated protein kinase homologues in the regulation of lipopolysaccharide-mediated induction of cyclo-oxygenase-2 but not nitric oxide synthase in RAW 264.7 macrophages
188. Activation of cytosolic phospholipase A2 by platelet-derived growth factor is essential for cyclooxygenase-2 -dependent prostaglandin E2 synthesis in mouse osteoblasts cultured with interleukin-1
189. Activation of arachidonate release and cytosolic phospholipase A2 via extracellular signal-regulated kinase and p38 mitogenactivated protein kinase in macrophages stimulated by bacteria or zymosan
190. The role of calcium and phosphorylation of cytosolic phospholipase A2 in regulating arachidonic acid release in macrophages
191. PLA2 phosphorylation and cyclooxygenase-2 induction, through p38 MAP kinase pathway, is involved in the IL-1beta-induced bradykinin B2 receptor gene transcription
192. Protein kinase C-dependent activation of cytosolic phospholipase A2 and mitogen-activated protein kinase by alpha 1-adrenergic receptors in Madin-Darby canine kidney cells
193. Signal transduction cascade in staurosporine-induced prostaglandin E(2) production by rat peritoneal macrophages
194. Cyclooxygenases: Structural, cellular, and molecular biology
195. The neuronal MAP kinase cascade: A biochemical signal integration system subserving synaptic plasticity and memory
196. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade
197. Effect of endotoxin and interleukin1beta on corticotropin-releasing-factor and prostaglandin release by rat brainstem slices
198. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA
199. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38
200. Analgesic and neurotoxic effects of intrathecal corticosteroids in rats
201. Role of glucocorticoids in the regulation of brain prostaglandin biosynthesis under basal conditions and in response to endotoxin
202. An N-methyl-D-aspartate antagonist, MN-801, preferentially reduces electroconvulsive shock-induced phosphorylation of p38 mitogen-activated protein kinase in the rat hippocampus
203. Neurotransmitter regulation of MAP kinase signaling in striatal neurons in primary culture
204. Intrathecal administration of p38 MAP Kinase inhibitor reduces inflammatory and NMDA induced hyperalgesia and prevents upregulaion of spinal COX-2
205. The role of COX 1 and COX 2 in the antihyperalgesic action of NSAIDs
206. Analgesic effect of indomethacin shown using the nociceptive flexion reflex in humans
207. Central analgesic effect of acetaminophen but not of aspirin
208. Central analgesic effect of ketoprofen in humans: Electrophysiological evidence for a supraspinal mechanism in a doubleblind and cross-over study
209. Piroxicaminduced analgesia: Evidence for a central component which is not opioid mediated
210. Small intrathecal doses of lysine-acetylsalicylate relieve intractable pain in man
211. Chronic refractory pain in cancer patients. Value of the spinal injection of lysine acetylsalicylate. 60 cases
212. Celecoxib clinical profile
213. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparatorcontrolled clinical trial
214. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice
215. Celecoxib versus diclofenac in the management of osteoarthritis of the knee
216. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug
217. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
218. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons
219. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout